Page last updated: 2024-12-07

stibocaptate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Stibocaptate, also known as sodium stibogluconate, is an antimonial drug used for the treatment of leishmaniasis. It is a complex of antimony(V) with gluconic acid. Stibocaptate is administered intravenously or intramuscularly. The exact mechanism of action is not fully understood, but it is thought to interfere with the metabolism of parasitic protozoa, leading to their death. Stibocaptate is effective against a variety of Leishmania species, including Leishmania donovani, Leishmania braziliensis, and Leishmania tropica. However, it has several adverse effects, including hepatotoxicity, cardiotoxicity, and nephrotoxicity. The drug is also associated with resistance development. Despite its toxicity, stibocaptate remains a valuable treatment option for leishmaniasis, especially in developing countries where other treatment options are not readily available. Research on stibocaptate focuses on developing safer and more effective antimonial drugs, understanding the mechanism of action, and overcoming drug resistance. '

stibocaptate: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID92908
MeSH IDM0045497

Synonyms (11)

Synonym
stibocaptate
1986-66-9
9wci9n7uuq ,
2,2'-((1,2-dicarboxyethylene)bis(thio))bis(1,3,2-dithiastibolane-4,5-dicarboxylic) acid
einecs 217-858-9
unii-9wci9n7uuq
astiban acid
succinic acid, 2,3-dimercapto-, cyclic thioantimonate(iii), s,s-diester with 2,3-dimercaptosuccinic acid
1,3,2-dithiastibolane-4,5-dicarboxylic acid, 2,2'-((1,2-dicarboxy-1,2-ethanediyl)bis(thio))bis-
Q27273317
2-[1,2-dicarboxy-2-[(4,5-dicarboxy-1,3,2-dithiastibolan-2-yl)sulfanyl]ethyl]sulfanyl-1,3,2-dithiastibolane-4,5-dicarboxylic acid

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" In vivo effectiveness may depend on bioavailability of Sb in the host and the direct action on the parasite, reflected by its in vitro activity."( Antitrypanosomal activity of trivalent antimonials in vitro and its significance.
Ercoli, N; Minelli, EB; Olivo, N, 1980
)
0.26

Dosage Studied

ExcerptRelevanceReference
"The effects of Astiban, Lucanthone, Hycanthone and Niridazole on autophagic activities in the gastrodermis of Schistosoma mansoni were determined in vivo, using different dosage levels and dosage times."( Schistosoma mansoni: an in vivo study of drug-induced autophagy in the gastrodermis.
Clarkson, J; Erasmus, DA, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-199040 (95.24)18.7374
1990's2 (4.76)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies3 (6.52%)4.05%
Observational0 (0.00%)0.25%
Other43 (93.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]